Strs Ohio Arcturus Therapeutics Holdings Inc. Transaction History

Strs Ohio

$23.2 Billion
Q1 2025

A detailed history of Strs Ohio transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Strs Ohio holds 8,400 shares of ARCT stock, worth $99,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,400

Previous 13,300 36.84%

Holding current value

$99,288

Previous $308,000 71.43%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 28, 2025	SELL	$10.59 - $20.83 $51,891 - $102,066	-4,900 Reduced 36.84%	8,400 $88,000
Q3 2024 Nov 01, 2024	SELL	$18.08 - $25.38 $83,167 - $116,748	-4,600 Reduced 25.7%	13,300 $308,000
Q2 2024 Aug 05, 2024	BUY	$24.35 - $44.39 $43,830 - $79,902	1,800 Added 11.18%	17,900 $435,000
Q1 2024 May 13, 2024	SELL	$31.23 - $42.99 $284,193 - $391,209	-9,100 Reduced 36.11%	16,100 $543,000
Q4 2023 Jan 30, 2024	BUY	$17.71 - $32.97 $70,840 - $131,880	4,000 Added 18.87%	25,200 $794,000
Q3 2023 Oct 26, 2023	SELL	$25.44 - $37.35 $68,688 - $100,845	-2,700 Reduced 11.3%	21,200 $541,000
Q2 2023 Jul 31, 2023	BUY	$23.94 - $32.36 $572,166 - $773,404	23,900 New	23,900 $685,000
Q3 2021 Oct 22, 2021	BUY	$27.88 - $58.25 $119,884 - $250,475	4,300 New	4,300 $205,000
Q1 2021 Apr 23, 2021	SELL	$38.75 - $86.92 $42,625 - $95,612	-1,100 Closed	0 $0
Q4 2020 Jan 25, 2021	SELL	$34.61 - $123.66 $76,142 - $272,052	-2,200 Reduced 66.67%	1,100 $47,000
Q2 2020 Jul 23, 2020	BUY	$12.66 - $58.27 $41,778 - $192,291	3,300 New	3,300 $154,000

Others Institutions Holding ARCT

# of Institutions

161

Shares Held

26.5M

Call Options Held

312K

Put Options Held

96.5K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $314M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.

Account